Futura Medical due $5m milestone payment from Haleon
Futura Medical
32.55p
11:50 21/11/24
-2.18%
-0.72p
Futura Medical, the consumer healthcare company behind Eroxon, announced on Monday that a $5m milestone payment had been triggered under its agreement with consumer products giant Haleon.
FTSE 100
8,111.29
11:50 21/11/24
n/a
n/a
FTSE 350
4,468.74
11:50 21/11/24
n/a
n/a
FTSE AIM All-Share
724.41
11:50 21/11/24
n/a
n/a
FTSE All-Share
4,425.83
11:50 21/11/24
n/a
n/a
Haleon
371.10p
11:50 21/11/24
0.68%
2.50p
Pharmaceuticals & Biotechnology
19,367.08
11:50 21/11/24
0.56%
107.94
The AIM-traded firm said the milestone followed the successful distribution of online pre-orders and the availability of Eroxon in US retail stores.
It said the payment was expected to be received shortly.
Eroxon, Futura’s flagship product, is a clinically-proven sexual health product.
The milestone payment was another key step in its ongoing strategy to commercialise its products globally, with the US launch being a major milestone in the product’s growth.
At 1356 BST, shares in Futura Medical were up 2.77% at 33.45p.
Reporting by Josh White for Sharecast.com.